US23954D1090 - Common Stock
DAY ONE BIOPHARMACEUTICALS I
NASDAQ:DAWN (3/28/2024, 3:24:54 PM)
16.7
+0.91 (+5.76%)
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 133 full-time employees. The company went IPO on 2021-05-27. The firm is focused on developing and commercializing targeted therapies for patients of all ages with life threatening diseases. The firm seeks to identify, acquire and develop product candidates that target high-value oncogenic drivers in cancers with unmet needs, with an initial focus on pediatric patients. Its lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the MAPK pathway. The company has initiated an open-label, multicenter, Phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib monotherapy or combination therapy, which consists of two substudies, such as Substudy 1 and Substudy 2.
DAY ONE BIOPHARMACEUTICALS I
2000 Sierra Point Parkway, Suite 501
Brisbane California CALIFORNIA
P: 16504840899
CEO: Jeremy Bender
Employees: 133
Website: https://dayonebio.com/
Day One Biopharmaceuticals reported a Q4 net loss of $54.5 million and ended 2023 with $366.3 million in cash, ensuring financial stability until 2026.
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational...
Here you can normally see the latest stock twits on DAWN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: